Editor’s Corner: Fierce Pharma gets a fierce makeovernews2022-02-25T14:38:11+00:00February 25th, 2022|Fierce Pharma|
Fierce Pharma Asia—Enhertu’s HER2-low breast cancer win; Takeda’s $2B gene therapy pact; Xtandi march-in campaignnews2022-02-25T11:53:59+00:00February 25th, 2022|Fierce Pharma|
Horizon joins with internet sensation to bring lyrical awareness to rare diseasesnews2022-02-25T11:36:12+00:00February 25th, 2022|Fierce Pharma|
Eli Lilly, Boehringer Ingelheim’s Jardiance clinches heart failure edge with FDA nod for wider labelnews2022-02-24T19:11:48+00:00February 24th, 2022|Fierce Pharma|
Teva, Endo and more back on the hook in San Francisco opioid trialnews2022-02-24T16:23:23+00:00February 24th, 2022|Fierce Pharma|
Merck KGaA pledges $550M in manufacturing upgrades after closing buyout of mRNA CDMO Exeleadnews2022-02-24T16:20:33+00:00February 24th, 2022|Fierce Pharma|
GlaxoSmithKline, Medicago’s plant-based COVID vaccine, Covifenz, wins first approvalnews2022-02-24T16:17:05+00:00February 24th, 2022|Fierce Pharma|
BioMarin eyes first profits in 2022 as dwarfism drug launch kicks into gear, hemophilia gene therapy refiling nearsnews2022-02-24T15:12:25+00:00February 24th, 2022|Fierce Pharma|
FDA will limit the use of GlaxoSmithKline and Vir’s COVID-19 antibody treatment in some geographic areasnews2022-02-24T14:54:04+00:00February 24th, 2022|Fierce Pharma|
WHO expands mRNA tech transfer to more countries in battle against COVIDnews2022-02-24T13:59:41+00:00February 24th, 2022|Fierce Pharma|
